DP
Dr. Paul Averback, MD, FRCP(C)
Founder, Chief Executive Officer, and Chairman of the Board
Nymox PharmaceuticalTherapeutic Areas
Nymox Pharmaceutical Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Fexapotide Triflutate (NX-1207) | Benign Prostatic Hyperplasia (BPH) | Phase 3 |